Zydus Pharmaceuticals, USA, has signed a license and supply agreement with Italy’s CHEMI SpA or CHEMI – a subsidiary of Italfarmaco Group, to launch Enoxaparin Sodium Injection in the United States (USA). The injection is usually given to patients undergoing abdominal, knee, or hip replacement surgery.
The product is a generic equivalent of Sanofi Aventis’ branded Lovenox product, according to a regulatory filing from Cadila Healthcare at the exchanges today. Zydus Pharma Inc, USA is a 100 percent subsidiary of Cadila Healthcare Limited or Zydus Cadila.
As part of the agreement, CHEMI will manufacture and supply the Enoxaparin Sodium Injection that will market Zydus Cadila in the United States. Using their proprietary technology, CHEMI will manufacture the Enoxaparin Sodium Injection at its own manufacturing facilities in Italy.
According to the statement, the leading specialty pharmaceutical company owns the proprietary rights to a pharmaceutical product consisting of preservative-free Enoxaparin Sodium pre-filled syringes.
The Enoxaparin Sodium Injection is used to treat deep vein thrombosis or DVT in patients undergoing abdominal, hip, or knee replacement surgery. The injection is also given to treat acute DVT. Enoxaparin acts as a blood thinner by producing an antithrombotic effect, Cadila Healthcare added in its statement. The injection had annual sales of approximately $513 million in the United States, according to IQVIA data as of June 2021.
On Friday, August 20, shares of Cadila Healthcare last traded 1.43 percent lower at Rs 534.95 on the BSE. Cadila Healthcare opened on the BSE at Rs 540, creeping up to an intraday high of Rs 547.85 and an intraday low of Rs 522, in the session so far.